Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5% After Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 5% during trading on Friday following insider selling activity. The stock traded as low as $3.54 and last traded at $3.5350. Approximately 3,552,628 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 21,216,084 shares. The stock had previously closed at $3.72.

Specifically, CFO Ben R. Taylor sold 13,426 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $3.08, for a total transaction of $41,352.08. Following the sale, the chief financial officer owned 1,195,349 shares of the company’s stock, valued at approximately $3,681,674.92. The trade was a 1.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Wall Street Analysts Forecast Growth

Several research firms recently commented on RXRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $9.40.

More Recursion Pharmaceuticals News

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: ARK Invest/Cathie Wood bought RXRX shares, signaling conviction from a high-profile active investor and providing buying support amid recent weakness. Cathie Wood ARK ETF Buys Recursion Pharmaceuticals and CRISPR Therapeutics Shares
• Neutral Sentiment: Analyst and institutional picture is mixed — some firms (e.g., JPMorgan/Morgan Stanley/UBS in prior coverage) have high targets ~ $11 while consensus remains closer to a “Hold” and average target near $9–10, leaving valuation views split. High institutional ownership means large holders can amplify moves. MarketBeat RXRX Coverage
• Negative Sentiment: NVIDIA liquidated its entire stake in Recursion at the end of last year — a high-profile exit that markets interpret as reduced strategic endorsement and that may have pressured sentiment. Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street.
• Negative Sentiment: Reports say major backers are exiting while Recursion doubles down on its REC‑102 program — investor concern around program risk and funding runway can trigger re-pricing until clinical data reduces uncertainty. Major Backers Exit As Recursion Deepens Commitment To REC-102 Pipeline
• Negative Sentiment: An insider selling disclosure: CFO Ben Taylor sold 13,426 shares at roughly $3.08 on Feb 18 — a small amount relative to his holding but often interpreted negatively in a down market. Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Sells 13,426 Shares of Stock

Recursion Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. The stock has a market cap of $1.78 billion, a P/E ratio of -1.90 and a beta of 0.95. The business’s 50-day moving average price is $4.25 and its 200-day moving average price is $4.76.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its holdings in shares of Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after buying an additional 6,699 shares in the last quarter. Royal Bank of Canada increased its holdings in Recursion Pharmaceuticals by 627.6% in the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after acquiring an additional 232,038 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Recursion Pharmaceuticals by 7.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock worth $953,000 after purchasing an additional 12,372 shares in the last quarter. Finally, Focus Partners Wealth bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $77,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.